株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

全身性エリテマトーデス (SLE) 市場・予測分析

Systemic Lupus Erythematosus (SLE) Market and Forecast Analysis

発行 Datamonitor Healthcare 商品コード 365197
出版日 ページ情報 英文 188 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.63円で換算しております。
Back to Top
全身性エリテマトーデス (SLE) 市場・予測分析 Systemic Lupus Erythematosus (SLE) Market and Forecast Analysis
出版日: 2017年03月01日 ページ情報: 英文 188 Pages
概要

当レポートでは、全身性エリテマトーデス (SLE) の上市済み薬剤およびパイプライン薬を調査し、 疾患の概要、主な上市済み薬剤のプロファイル、地域/国別の売上の推移と予測、パイプライン後期の薬剤のプロファイル、今後の展望などをまとめています。

予測:全身性エリテマトーデス

  • エグゼクティブサマリー
  • 市場概要・動向
  • 市場の定義・調査手法
  • anifrolumab
  • Benlysta SLE (belimumab)
  • blisibimod
  • 主要調査手法

疫学:全身性エリテマトーデス

  • エグゼクティブサマリー
  • 疾患の背景
  • 情報源・調査手法
  • 予測
  • 疫学者による考察
  • 強み・制約
  • 付録

上市済み薬剤:全身性エリテマトーデス

  • エグゼクティブサマリー
  • 製品概要
  • 主要調査手法
  • 製品プロファイル:Benlysta
  • 製品プロファイル:オフラベル:CellCept
  • 製品プロファイル:オフラベル:Rituxan

パイプライン:全身性エリテマトーデス

  • エグゼクティブサマリー
  • 臨床パイプラインの概要
  • 比較療法
  • 臨床試験設計
  • 最近中止された薬剤
  • 製品プロファイル (後期):Lupuzor
  • 製品プロファイル (後期):Orencia
  • 製品プロファイル (後期):anifrolumab
  • 製品プロファイル (後期):atacicept
  • 製品プロファイル (後期):blisibimod
  • 図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: DMKC5364

Disease Overview

Lupus is a chronic inflammatory autoimmune disorder that can affect many different body systems, including the joints, skin, kidneys, blood cells, brain, heart, and lungs. Systemic lupus erythematosus refers to the systemic form of the disease, which includes organ-specific variants, such as lupus nephritis. This disorder can be very difficult to diagnose as its signs and symptoms often mimic those of other conditions, and a physician is unlikely to ever see two cases that are alike. The most concerning symptoms are the ones that do not currently respond well to treatment, including renal and neurologic symptoms, as these can cause severe morbidity, disability, and ultimately fatal outcomes. Benlysta (belimumab; GlaxoSmithKline) became the first new therapy for lupus in over 50 years when it gained approval in

2011. However, despite significant hype surrounding its launch, uptake has been low, and the market remains open and eager for effective targeted therapies.

TABLE OF CONTENTS

FORECAST: SYSTEMIC LUPUS ERYTHEMATOSUS

  • Executive Summary
  • Market Overview and Trends
  • Market Definition and Methodology
  • anifrolumab
  • Benlysta SLE (belimumab)
  • blisibimod
  • Primary Research Methodology

EPIDEMIOLOGY: SYSTEMIC LUPUS ERYTHEMATOSUS

  • Executive Summary
  • Disease Background
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations
  • Appendix: Additional Sources

MARKETED DRUGS: SYSTEMIC LUPUS ERYTHEMATOSUS

  • Executive Summary
  • Product Overview
  • Primary Research Methodology
  • Product profile: Benlysta
  • Product profile: Off-label: CellCept
  • Product profile: Off-label: Rituxan

PIPELINE: SYSTEMIC LUPUS ERYTHEMATOSUS

  • Executive Summary
  • Clinical Pipeline Overview
  • Comparator Therapy
  • Clinical Trial Design
  • Recently Discontinued Drugs
  • Product profile (late stage): Lupuzor
  • Product profile (late stage): Orencia
  • Product profile (late stage): anifrolumab
  • Product profile (late stage): atacicept
  • Product profile (late stage): blisibimod

LIST OF FIGURES

  • Figure 1: Timeline: approval/launch dates of key systemic lupus erythematosus therapies
  • Figure 2: Systemic lupus erythematosus sales in the US, by brand ($m), 2015-24
  • Figure 3: Systemic lupus erythematosus sales in the five major EU markets, by brand ($m), 2015-24
  • Figure 4: Patient-based forecast methodology for systemic lupus erythematosus
  • Figure 5: Price sources and calculations, by country
  • Figure 6: Anifrolumab forecast sales for systemic lupus erythematosus in the US and five major EU markets ($m), 2015-24
  • Figure 7: Benlysta forecast sales for systemic lupus erythematosus in the US and five major EU markets ($m), 2015-24
  • Figure 8: Blisibimod forecast sales for systemic lupus erythematosus in the US and five major EU markets ($m), 2015-24
  • Figure 9: Trends in age-specific diagnosed prevalent cases of SLE in the US, Japan, and five major EU markets, 2015-35
  • Figure 10: Absolute change in diagnosed prevalent cases of SLE in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 11: Benlysta for systemic lupus erythematosus - SWOT analysis
  • Figure 12: Datamonitor Healthcare's drug assessment summary of Benlysta for systemic lupus erythematosus
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Benlysta for systemic lupus erythematosus
  • Figure 14: CellCept for systemic lupus erythematosus - SWOT analysis
  • Figure 15: Datamonitor Healthcare's drug assessment summary of CellCept for systemic lupus erythematosus
  • Figure 16: Datamonitor Healthcare's drug assessment summary of CellCept for systemic lupus erythematosus
  • Figure 17: Rituxan for systemic lupus erythematosus - SWOT analysis
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Rituxan for systemic lupus erythematosus
  • Figure 19: Datamonitor Healthcare's drug assessment summary of Rituxan for systemic lupus erythematosus
  • Figure 20: Lupuzor for systemic lupus erythematosus - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Lupuzor for systemic lupus erythematosus
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Lupuzor for systemic lupus erythematosus
  • Figure 23: Orencia for systemic lupus erythematosus - SWOT analysis
  • Figure 24: Datamonitor Healthcare's drug assessment summary of Orencia for systemic lupus erythematosus
  • Figure 25: Datamonitor Healthcare's drug assessment summary of Orencia for systemic lupus erythematosus
  • Figure 26: Anifrolumab for systemic lupus erythematosus - SWOT analysis
  • Figure 27: Datamonitor Healthcare's drug assessment summary of anifrolumab for systemic lupus erythematosus
  • Figure 28: Datamonitor Healthcare's drug assessment summary of anifrolumab for systemic lupus erythematosus
  • Figure 29: Atacicept for systemic lupus erythematosus - SWOT analysis
  • Figure 30: Datamonitor Healthcare's drug assessment summary of atacicept for systemic lupus erythematosus
  • Figure 31: Datamonitor Healthcare's drug assessment summary of atacicept for systemic lupus erythematosus
  • Figure 32: Blisibimod for systemic lupus erythematosus - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary of blisibimod for systemic lupus erythematosus
  • Figure 34: Datamonitor Healthcare's drug assessment summary of blisibimod for systemic lupus erythematosus

LIST OF TABLES

  • Table 1: Systemic lupus erythematosus sales in the US, by brand ($m), 2015-24
  • Table 2: Systemic lupus erythematosus sales in the five major EU markets, by brand ($m), 2015-24
  • Table 3: Estimated launch dates for key late-stage pipeline products and marketed brands in systemic lupus erythematosus,2015-24
  • Table 4: Exchange rates used for calculating prices
  • Table 5: Anifrolumab forecast sales for systemic lupus erythematosus in the US and five major EU markets ($m), 2015-24
  • Table 6: Benlysta forecast sales for systemic lupus erythematosus in the US and five major EU markets ($m), 2015-24
  • Table 7: Blisibimod forecast sales for systemic lupus erythematosus in the US and five major EU markets ($m), 2015-24
  • Table 8: Rheumatologists surveyed for the systemic lupus erythematosus primary research study, 2011
  • Table 9: Sources used for the epidemiological analysis of SLE in the US, Japan, and five major EU markets, by country
  • Table 10: Sources not used for the epidemiological analysis of SLE in the US, Japan, and five major EU markets, by country
  • Table 11: Diagnosed prevalent cases of SLE in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 12: Age-specific diagnosed prevalent cases of SLE in the US, Japan, and five major EU markets, by country, 2015
  • Table 13: Gender-specific diagnosed prevalent cases of SLE in the US, Japan, and five major EU markets, by country, 2015
  • Table 14: Key marketed and off-label products for systemic lupus erythematosus
  • Table 15: Rheumatologists surveyed for the systemic lupus erythematosus primary research study, 2016
  • Table 16: Benlysta drug profile
  • Table 17: Benlysta IV pivotal trial data in systemic lupus erythematosus
  • Table 18: Benlysta SC late-phase trial data in systemic lupus erythematosus
  • Table 19: Benlysta IV ongoing late-phase trials in systemic lupus erythematosus
  • Table 20: Average future usage of biosimilar rituximab when it becomes available, according to rheumatologists surveyed from the US and five major EU markets (France, Germany, Italy, Spain, and the UK), by severity
  • Table 21: CellCept drug profile
  • Table 22: CellCept Phase III data in systemic lupus erythematosus - lupus nephritis
  • Table 23: Rituxan drug profile
  • Table 24: Rituxan pivotal trial data in systemic lupus erythematosus
  • Table 25: Average future usage of biosimilar rituximab when it becomes available, according to rheumatologists surveyed from the US and five major EU markets (France, Germany, Italy, Spain, and the UK), by severity
  • Table 26: Phase III pipeline products in development for systemic lupus erythematosus
  • Table 27: Benlysta drug profile
  • Table 28: Benlysta IV pivotal trial data in systemic lupus erythematosus
  • Table 29: Summary of formal FDA guidance for industry in systemic lupus erythematosus
  • Table 30: Summary of formal FDA guidance for industry in lupus nephritis
  • Table 31: Summary of formal EMA guidance for industry in lupus nephritis
  • Table 32: Commonly used clinical trial endpoints for systemic lupus erythematosus
  • Table 33: Commonly used clinical trial endpoints for systemic lupus erythematosus - lupus nephritis
  • Table 34: Late-stage compounds that were recently discontinued for systemic lupus erythematosus
  • Table 35: Epratuzumab drug profile
  • Table 36: Epratuzumab trial data in systemic lupus erythematosus
  • Table 37: Lupuzor drug profile
  • Table 38: Lupuzor Phase III trials in systemic lupus erythematosus
  • Table 39: Lupuzor Phase IIb trial data in systemic lupus erythematosus
  • Table 40: Orencia drug profile
  • Table 41: Orencia ongoing late-phase trials in systemic lupus erythematosus
  • Table 42: Orencia Phase III data in systemic lupus erythematosus
  • Table 43: Anifrolumab drug profile
  • Table 44: Anifrolumab Phase III trials in systemic lupus erythematosus
  • Table 45: Anifrolumab Phase IIb data in systemic lupus erythematosus
  • Table 46: Atacicept drug profile
  • Table 47: Atacicept Phase III data in systemic lupus erythematosus
  • Table 48: Blisibimod drug profile
  • Table 49: Blisibimod Phase III data in systemic lupus erythematosus
  • Table 50: Blisibimod Phase III trials in systemic lupus erythematosus
Back to Top